Description
Retatrutide + Cagrilintide research blend
Retatrutide + Cagrilintide combines retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, with cagrilintide, a long-acting amylin analogue, in one vial. The pairing reflects research interest in combining incretin and amylin pathways.
Product details
| Compound | Retatrutide and Cagrilintide |
|---|---|
| Class | Two-peptide metabolic research blend |
| Format | Lyophilised peptide vial |
| Labelling | Compound name and strength on every container |
What Retatrutide + Cagrilintide research has examined
- Retatrutide: triple incretin/glucagon receptor agonism.
- Cagrilintide: amylin and calcitonin receptor signalling.
- Combination research: multi-pathway approaches in metabolic studies.
Research interest does not establish a proven effect in humans.
Regulatory status
Retatrutide + Cagrilintide is a research blend. None of its components is approved for human use in this form, and it is supplied as a research chemical only.
Storage and handling
Store lyophilised vials cold, dry and away from light. Reconstitute with a suitable sterile diluent under aseptic conditions and keep solutions refrigerated. See our peptide reconstitution guide.
Related research products
Adamax / Adalank Combo Pack · Healing Research Bundle · Turn Back Time Bundle · All peptides
References
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Reviews
There are no reviews yet.